Investing.com - Immunovant (NASDAQ: IMVT) reported second quarter EPS of $-0.57, $0.13 worse than the analyst estimate of $-0.44. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.
Immunovant's stock price closed at $20.92. It is up 16.55% in the last 3 months and up 312.67% in the last 12 months.
Immunovant saw 0 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Immunovant's stock price’s past reactions to earnings here.
According to InvestingPro, Immunovant's Financial Health score is "good performance".
Check out Immunovant's recent earnings performance, and Immunovant's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar